vs
Side-by-side financial comparison of Acadian Asset Management Inc. (AAMI) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $172.2M, roughly 1.7× Acadian Asset Management Inc.). Acadian Asset Management Inc. runs the higher net margin — 20.2% vs 12.8%, a 7.3% gap on every dollar of revenue. On growth, Acadian Asset Management Inc. posted the faster year-over-year revenue change (2.6% vs -6.4%). Over the past eight quarters, Acadian Asset Management Inc.'s revenue compounded faster (27.6% CAGR vs 4.2%).
United Asset Management was an American holding company headquartered in Boston, Massachusetts.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
AAMI vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $172.2M | $295.9M |
| Net Profit | $34.7M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | 33.3% | 18.4% |
| Net Margin | 20.2% | 12.8% |
| Revenue YoY | 2.6% | -6.4% |
| Net Profit YoY | -18.4% | 68.3% |
| EPS (diluted) | $0.97 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $172.2M | $295.9M | ||
| Q3 25 | $144.2M | — | ||
| Q2 25 | $127.4M | $317.0M | ||
| Q1 25 | $119.9M | $316.2M | ||
| Q4 24 | $167.8M | $297.0M | ||
| Q3 24 | $123.1M | $289.5M | ||
| Q2 24 | $109.0M | $306.1M | ||
| Q1 24 | $105.7M | $303.4M |
| Q4 25 | $34.7M | $38.0M | ||
| Q3 25 | $15.1M | — | ||
| Q2 25 | $10.1M | $-17.7M | ||
| Q1 25 | $20.1M | $22.6M | ||
| Q4 24 | $42.5M | $34.9M | ||
| Q3 24 | $16.9M | $33.6M | ||
| Q2 24 | $11.0M | $40.6M | ||
| Q1 24 | $14.6M | $49.1M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% | ||
| Q1 24 | — | 67.4% |
| Q4 25 | 33.3% | 18.4% | ||
| Q3 25 | 18.4% | — | ||
| Q2 25 | 12.7% | -7.5% | ||
| Q1 25 | 26.6% | 12.2% | ||
| Q4 24 | 38.7% | 16.0% | ||
| Q3 24 | 21.9% | 13.8% | ||
| Q2 24 | 18.9% | 15.0% | ||
| Q1 24 | 21.7% | 22.1% |
| Q4 25 | 20.2% | 12.8% | ||
| Q3 25 | 10.5% | — | ||
| Q2 25 | 7.9% | -5.6% | ||
| Q1 25 | 16.8% | 7.1% | ||
| Q4 24 | 25.3% | 11.7% | ||
| Q3 24 | 13.7% | 11.6% | ||
| Q2 24 | 10.1% | 13.3% | ||
| Q1 24 | 13.8% | 16.2% |
| Q4 25 | $0.97 | $0.24 | ||
| Q3 25 | $0.42 | — | ||
| Q2 25 | $0.28 | $-0.11 | ||
| Q1 25 | $0.54 | $0.14 | ||
| Q4 24 | $1.11 | $0.22 | ||
| Q3 24 | $0.45 | $0.21 | ||
| Q2 24 | $0.29 | $0.26 | ||
| Q1 24 | $0.37 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $172.9M |
| Total DebtLower is stronger | $200.0M | $260.0M |
| Stockholders' EquityBook value | — | $2.0B |
| Total Assets | $677.0M | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $172.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $162.2M | ||
| Q1 25 | — | $140.7M | ||
| Q4 24 | — | $177.5M | ||
| Q3 24 | — | $187.5M | ||
| Q2 24 | — | $152.9M | ||
| Q1 24 | — | $145.3M |
| Q4 25 | $200.0M | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | $275.0M | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
| Q4 25 | — | $2.0B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $2.0B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.1B | ||
| Q2 24 | — | $2.1B | ||
| Q1 24 | — | $2.0B |
| Q4 25 | $677.0M | $2.5B | ||
| Q3 25 | $751.4M | — | ||
| Q2 25 | $672.3M | $2.6B | ||
| Q1 25 | $677.3M | $2.6B | ||
| Q4 24 | $703.2M | $2.7B | ||
| Q3 24 | $555.2M | $2.7B | ||
| Q2 24 | $533.1M | $2.7B | ||
| Q1 24 | $544.9M | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.4M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -0.07× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.4M | — | ||
| Q3 25 | $-23.9M | — | ||
| Q2 25 | $61.6M | $98.2M | ||
| Q1 25 | $-48.8M | $41.1M | ||
| Q4 24 | $55.8M | $84.3M | ||
| Q3 24 | $69.6M | $63.9M | ||
| Q2 24 | $45.7M | $75.5M | ||
| Q1 24 | $-40.4M | $81.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $93.3M | ||
| Q1 25 | — | $31.0M | ||
| Q4 24 | — | $77.5M | ||
| Q3 24 | — | $54.7M | ||
| Q2 24 | — | $57.5M | ||
| Q1 24 | — | $64.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 29.4% | ||
| Q1 25 | — | 9.8% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 18.9% | ||
| Q2 24 | — | 18.8% | ||
| Q1 24 | — | 21.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 3.2% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | 5.9% | ||
| Q1 24 | — | 5.4% |
| Q4 25 | -0.07× | — | ||
| Q3 25 | -1.58× | — | ||
| Q2 25 | 6.10× | — | ||
| Q1 25 | -2.43× | 1.82× | ||
| Q4 24 | 1.31× | 2.42× | ||
| Q3 24 | 4.12× | 1.90× | ||
| Q2 24 | 4.15× | 1.86× | ||
| Q1 24 | -2.77× | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AAMI
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
